DRugwatch BlogRSS 2.0

DRugwatch Blog > February 2012

  • 2/23/2012 3:16:55 PM
    FDA Advisory Committee Get Behind Qnexa
    Contributor: Gideon Heap

    After a second FDA Advisory Committee meeting, Qnexa received a landslide 20-2 vote in favor of approval. Opinion seems to have turned in...
  • 2/14/2012 3:06:54 PM
    Finally! The FDA Issues Draft Guidance for Biosimilars
    Matt Kileen
  • 2/7/2012 5:51:17 PM
    Good News for Bydureon, but Bad News for Dapagliflozin
    Matt Kileen 2/7/2012 1:44:31 PM
    MDV3100 - Another Novel Agent Extends the Menu of Treatment Options for Prostate Cancer
    Matt Kileen


    rss twitter linkedin


    DRugwatch Blog

    Quick insight on intriguing drug market developments from Decision Resources’ analysts.

    Recent posts

    Post title:
    What’s going to be Hot at the 2014 AHA Scientific Sessions?
    Post date:
    10/22/2014 5:22:24 PM
    Post Summary:
      Contributor: Conor Walsh

     This year’s line-up of Late-Breaking Clinical Trial sessions looks very interesting; with many trials having the   potential to significantly impact clinical practice. The trial results will be presented over four days in separate sessions focusing on:

    • Risk and benefit of dual antiplatelet therapy (DAPT),
    • Anti-lipid therapy and prevention of coronary artery disease,
    • Treatment of structural heart disease
    • Drugs, devices and systems of care for ischemic heart disease.

    Post title:
    Advancing the Treatment of TKI-refractory NSCLC
    Post date:
    10/9/2014 1:33:46 PM
    Post Summary:
    Contributor: Orestis Mavroudis-Chocholis

    NSCLC is considered by many to be the poster child for personalized medicine in oncology. The approval of TKIs for the treatment of EGFR-mutation-positive and ALK-translocation-positive NSCLC patients has redefined the NSCLC treatment algorithm and developers are now in fierce competition to be the first to market novel, more efficacious and better tolerated TKIs which can be used as follow-on treatment options or replacements for currently approved front-line TKIs.

    Post title:
    Realizing the Potential of HPV-associated Cancer Prevention
    Post date:
    10/8/2014 10:15:17 AM
    Post Summary:
    Contributors: Kirsha Naicker and Dan Roberts

    HPV vaccinations were voted by ASCO this year to be one of the top five advances in modern oncology in the past 50 years.

    Post title:
    Gastric Cancer: The Ghosts of Past, Present and Future
    Post date:
    10/7/2014 9:06:40 AM
    Post Summary:
    Contributor: Sehrish Rafique

    Companies are now striving towards developing targeted therapies for advanced gastric cancer. Exploiting biomarkers is a dominant strategy and clinical data presented at the recent ESMO conference highlighted significant advances in the treatment of gastric cancer.

    Post title:
    EASD 2014: SGLT-2 inhibitors, GLP-1 agonists, insulins, long-term study results, and speculations about triple combination therapies
    Post date:
    10/1/2014 3:05:08 PM
    Post Summary:
    Contributor: Stefanie Hoffart

    Between September 15 and 19, the European Association for the Study of Diabetes (EASD) meeting took place in Vienna, Austria, celebrating its 50th anniversary.

    Decision Resources Group brands include: